Blood Lipid-lowering Effect of Brown Alga Ecklonia Cava

Chonbuk National University

Status and phase: Completed; Phase 3; Phase 2

Conditions: Hypercholesterolemia

Treatments: Dietary Supplement: Placebo; Dietary Supplement: ECE (Ecklonia cava extract)

Study type: Interventional

Funder types: Other

Identifiers

NCT02091024

LVCM-HL-SEAPOLYNOL

Details and patient eligibility

About

The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Ecklonia cava extract on hyperlipidemia.

Full description

The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Ecklonia cava extract on hyperlipidemia. The investigators measured improvement of lipid profile, including total cholesterol, triglyceride, HDL-cholesterol, and LDL-cholesterol.

Enrollment: 80 patients

Sex: All

Ages: 19 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Mild hypercholesterolemic subjects(≥200mg/dL of total cholesterol or ≥110mg/dL of LDL-cholesterol)

Exclusion criteria

• Self-reported pregnancy, lactation
• Prevalent heart disease, cancer, renal disorder, or diabetes mellitus, and use of lipid-lowering drugs

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

80 participants in 2 patient groups, including a placebo group

ECG (Ecklonia cava extract)

Experimental group

Description:

ECE 200mg, twice a day

Treatment:

Dietary Supplement: ECE (Ecklonia cava extract)

Placebo

Placebo Comparator group

Description:

Placebo 200mg, twice a day

Treatment:

Dietary Supplement: Placebo